KRCA-0008

KRCA-0008 is a selective ALK/Ack1 inhibitor with IC50s of 12 and 4 nM for ALK and Ack1, respectively. KRCA-0008 can be used for the research of cancer[1][2].

Product Specifications

CAS Number

[1472795-20-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Ack1; Anaplastic lymphoma kinase (ALK) ; Apoptosis

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/KRCA-0008.html

Purity

96.72

Solubility

DMSO : 230 mg/mL (ultrasonic)

Smiles

ClC1=CN=C(NC2=CC=C(N3CCN(C(C)=O)CC3)C=C2OC)N=C1NC4=CC=C(N5CCN(C(C)=O)CC5)C=C4OC

Molecular Formula

C30H37ClN8O4

Molecular Weight

609.12

Precautions

H302, H315, H319, H335

References & Citations

[1]Park CH, et al. Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment. Bioorg Med Chem Lett. 2013 Nov 15;23 (22) :6192-6.|[2]Hwang J, et al. KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth. Invest New Drugs. 2020 Oct;38 (5) :1282-1291.